Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04962126
Title Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Olivia Newton-John Cancer Research Institute

follicular lymphoma


Atezolizumab + Obinutuzumab

Age Groups: adult | senior
Covered Countries

No variant requirements are available.